Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 15, 2008. The report details a specific corporate action regarding the company's share capital rather than providing comprehensive financial results for a fiscal period.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed relates to a share repurchase transaction:
- Shares Purchased: 1,500,000 Ordinary shares of 25 pence each.
- Purchase Date: May 15, 2008.
- Purchase Price: 1,125.57 pence per share.
- Treasury Holdings: Following cancellation, GSK holds 484,194,158 shares in Treasury, representing 9.03% of total voting rights.
- Shares in Issue: 5,361,920,376 (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the company's issued share capital through the cancellation of 1,500,000 shares. This action was executed under authority granted by shareholders at the Annual General Meeting on May 23, 2007. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,361,920,376) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (484,194,158) and its impact on the total voting rights percentage (9.03%).
- Note that this filing is a notification of a specific transaction and does not replace periodic financial reports (e.g., Form 20-F) for revenue or earnings data.